The increasing number of item dispatches or endorsements is supposed to help in supporting the development of the U.S. intravenous immunoglobulin market. On January 19, 2016, Kedrion Biopharma, an organization that creates plasma-determined treatments, reported that it had gotten select privileges to popularize another immunoglobulin (IG) brand—BIVIGAM, a 10% fluid authorized by Germany-based Biotest Pharmaceuticals Corporation—to extend its developing presence in the U.S. Kedrion Biopharma Inc. is the U.S. auxiliary of Kedrion Biopharma, a worldwide forerunner in the turn of events and assembling of helpful plasma proteins.
Request For Sample Report (Including Full TOC, Table & Figures) @
Expansion in the number of acquisitions, associations, and coordinated efforts between the market players is supposed to drive the development of the U.S. intravenous immunoglobulin market during the estimated timeframe. On June 06, 2017, ADMA Biologics, Inc., a late-stage biopharmaceutical organization that creates, produces, and popularizes specialty plasma-based biologics for the treatment of safe lacks and the counteraction of specific irresistible sicknesses, reported that it had finished its procurement of the resources of Biotest Pharmaceuticals Corporation’s Therapy Business Unit (BTBU). Due to this exchange, ADMA obtained two U.S. Food and Drug Administration (FDA) supported items, Nabi-HB (Hepatitis B Immune Globulin, Human) and BIVIGAM (Immune Globulin Intravenous, Human).
Effect of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has impacted a few business sectors across the globe. The COVID-19 pandemic has impacted the interest and supply of medical care items in three primary ways: by straightforwardly influencing the creation and request; by making disturbances in conveyance channels; and due to its monetary effect on firms and monetary business sectors.
Be that as it may, the effect of the COVID-19 pandemic is supposed to help the development of the U.S. intravenous immunoglobulin market. As per an article distributed in the journal International Immunopharmacology in July 2021, intravenous immunoglobulin (IVIG) showed clinical viability in basic sick patients with COVID-19. A relationship can be seen between the viability of IVIG and the seriousness of COVID-19 illness.
The U.S. intravenous immunoglobulin market is supposed to display a CAGR of 6.8 % over the conjecture period (2021-2028). Expanding innovative work exercises, rising item dispatches and endorsements, and inorganic exercises like coordinated efforts, arrangements, acquisitions, and others are supposed to drive the development of the S. intravenous immunoglobulin market. On February 9, 2021, Evolve Biologics Inc., a plasma-based therapeutics company, announced the completion of its adult and pediatric Phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or IVIG), which was conducted at 12 review sites across the United States and Canada. PlasmaCap IG is an IVIG trade treatment that is being studied for adult and pediatric patients with essential immune deficiency disease (PIDD).
Download PDF Brochure with Latest Insights @
Key companies contributing to the U.S. intravenous immunoglobulin market include McKesson Corporation, CSL Behring, Grifols S.A., Octapharma AG, Biotest AG, ADMA Biologics, Inc., Pfizer, Inc., Kedrion Biopharma, Inc., Bio Products Laboratory Ltd., and Takeda Pharmaceutical Company Limited.
Reasons to buy this U.S. Intravenous Immunoglobulin Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ U.S. Intravenous Immunoglobulin market size estimation and recent advancements in the industry are explained.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/4829
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 U.S. Intravenous Immunoglobulin Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: U.S. Intravenous Immunoglobulin Industry Impact
Chapter 2 Global U.S. Intravenous Immunoglobulin Competition by Types, Applications, and Top Regions and Countries
2.1 Global U.S. Intravenous Immunoglobulin (Volume and Value) by Type
2.3 Global U.S. Intravenous Immunoglobulin (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global U.S. Intravenous Immunoglobulin Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America U.S. Intravenous Immunoglobulin Market Analysis
Chapter 6 East Asia U.S. Intravenous Immunoglobulin Market Analysis
Chapter 7 Europe U.S. Intravenous Immunoglobulin Market Analysis
Chapter 8 South Asia U.S. Intravenous Immunoglobulin Market Analysis
Chapter 9 Southeast Asia U.S. Intravenous Immunoglobulin Market Analysis
Chapter 10 Middle East U.S. Intravenous Immunoglobulin Market Analysis
Chapter 11 Africa U.S. Intravenous Immunoglobulin Market Analysis
Chapter 12 Oceania U.S. Intravenous Immunoglobulin Market Analysis
Chapter 13 South America U.S. Intravenous Immunoglobulin Market Analysis
Chapter 14 Company Profiles and Key Figures in U.S. Intravenous Immunoglobulin Business
Chapter 15 Global U.S. Intravenous Immunoglobulin Market Forecast (2022-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027